Prosonitron^TM, DISCUS^®, SAX^TM,  UMAX^® SAX^TM  and PRT based process technologies are proprietary "Solution-to-Particle" methods for controlling crystal size, shape and polymorph for APIs and helping in the making better medicines. Technologies offer dose-to-dose uniformity, formulation consistency, stability and 200% performance increase of inhaled APIs compared to micronized. Combination particles of multiple APIs can be manufactured.